Who is sponsoring NCT01418430?

NCT01418430 is sponsored by King's College Hospital NHS Trust.

What drugs are being tested in NCT01418430?

Interventions in NCT01418430: CHOP-daclizumab.

What condition does NCT01418430 study?

NCT01418430 studies HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL).

Is NCT01418430 still recruiting?

NCT01418430 is currently completed. Last updated 19 August 2011.

Last reviewed 2011-08-19 · How we verify

NCT01418430

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)

Completed Phase 4 Last updated 19 August 2011

What this trial tests

Phase 4 trial testing CHOP-daclizumab in HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL). Completed.

Quick facts

Lead sponsor	King's College Hospital NHS Trust
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Primary purpose	treatment
Sites	1 location across United Kingdom

Drugs / interventions tested

CHOP-daclizumab — full drug profile →

Conditions studied

HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) — all drugs for HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) →

Sponsor

King's College Hospital NHS Trust

Who can join

Adults 18 to 75, any sex, with HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine the safety of the combination of CHOP plus daclizumab in patients with ATLL previously untreated with anthracycline based chemotherapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Recent Updates on Viral Oncogenesis: Available Preventive and Therapeutic Entities.
Chowdhary S, Deka R, Panda K, Kumar R, et al · · 2023 · cited 13× · PMID 37486263 · DOI 10.1021/acs.molpharmaceut.2c01080

Verify or expand the search:

Other King's College Hospital NHS Trust trials

Trials by the same sponsor.

NCT07384884 — Surgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas · NA · not yet recruiting
NCT07379723 — Brief Intervention for FCD: A Feasibility Study · NA · recruiting
NCT07062731 — Pelvic Floor Exercises for Suboptimal Anorectal Manometry · recruiting
NCT06766162 — Virtual Reality to Improve Patient Experience During Endoscopic Mucosal and Submucosal Resection · NA · completed
NCT06918756 — Development of a Cough Control Questionnaire (CCQ) · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01418430 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by King's College Hospital NHS Trust
Last refreshed: 19 August 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01418430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing